Literature DB >> 23559361

Autologous fibrin membrane combined with solid platelet-rich plasma in the management of perforated corneal ulcers: a pilot study.

Jorge L Alio1, Alejandra E Rodriguez, Lorena M Martinez, Alvaro Luque Rio.   

Abstract

IMPORTANCE: The combined use of autologous fibrin membrane and the eye platelet-rich plasma (E-PRP) clot could be considered as a new surgical alternative for the closure of corneal perforations.
OBJECTIVE: To evaluate the use of autologous solid platelet-rich plasma in combination with an autologous fibrin membrane as a surgical alternative for wound closure in perforated corneal ulcers.
DESIGN: Both the fibrin membrane and the E-PRP clot were prepared with the patient's own blood just before the operation. Nylon stitches were used to fixate the fibrin membrane to the conjunctiva and then the E-PRP clot was placed over the corneal perforation, underneath the fibrin membrane. A temporal partial tarsorrhaphy was performed at the end of the procedure. We conducted postoperative monitoring for 3 months. SETTING Vissum Corporacion Oftalmologica, Alicante, Spain. PARTICIPANTS: Eleven patients with perforated corneal ulcers. INTERVENTION: Surgical alternative for the closure of corneal perforation. MAIN OUTCOMES AND MEASURES: Corneal biomicroscopy, fluorescein test, digital tonometry.
RESULTS: In all cases the corneal perforation was sealed. The fibrin membrane was present over the corneal surface for the first 3 to 5 days and then gradually disappeared. No evidence of infection or inflammation was detected. Digital tonometry confirmed acceptable levels of ocular tonus in all cases from day 2 after the operation. No patients reported pain, discomfort, or other symptoms, and no complications were observed. After 3 months' follow-up, there was no evidence of relapses or perforations. Corneal grafting was eventually performed in 7 of the 11 cases. CONCLUSIONS AND RELEVANCE: The combined use of autologous fibrin membrane and E-PRP clot is a safe and effective surgical alternative for the closure of corneal perforations. This technique can be considered as a temporary measure until the condition of the cornea permits definite intervention.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23559361     DOI: 10.1001/jamaophthalmol.2013.2474

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  18 in total

1.  Platelet-rich fibrin sealant as a treatment for complex perianal fistulas: a multicentre study.

Authors:  F J Pérez Lara; A Moreno Serrano; J Ulecia Moreno; J Hernández Carmona; M Ferrer Marquez; L Romero Pérez; A del Rey Moreno; H Oliva Muñoz
Journal:  J Gastrointest Surg       Date:  2014-11-25       Impact factor: 3.452

2.  Use of autologous plasma rich in growth factors fibrin membrane in the surgical management of ocular surface diseases.

Authors:  Alfonso L Sabater; Hazem M Mousa; Xavier Quinones; Felipe Valenzuela; Ronald Mauricio Sanchez Avila; Gorka Orive; Eduardo Anitua; Jesús Merayo; Victor L Perez
Journal:  Int Ophthalmol       Date:  2021-03-21       Impact factor: 2.031

Review 3.  Solid Platelet Rich Plasma in Corneal Surgery.

Authors:  Francisco Arnalich; Alejandra E Rodriguez; Alvaro Luque-Rio; Jorge L Alio
Journal:  Ophthalmol Ther       Date:  2016-05-14

4.  Outcomes of Infectious versus Sterile Perforated Corneal Ulcers after Therapeutic Penetrating Keratoplasty in the United States.

Authors:  Sloan W Rush; Ryan B Rush
Journal:  J Ophthalmol       Date:  2016-12-13       Impact factor: 1.909

5.  The Effects of Platelet-Rich Fibrin Membrane on Secondary Healing After Pleomorphic Adenoma Excision in the Hard Palate: A Preliminary Study.

Authors:  Özer Erdem Gür; Nuray Ensari; Nevreste Didem Sonbay Yılmaz
Journal:  Ann Maxillofac Surg       Date:  2017 Jan-Jun

Review 6.  Application of Novel Drugs for Corneal Cell Regeneration.

Authors:  Sang Beom Han; Yu-Chi Liu; Karim Mohamed-Noriega; Jodhbir S Mehta
Journal:  J Ophthalmol       Date:  2018-05-02       Impact factor: 1.909

7.  Plasma rich in growth factors membrane as coadjuvant treatment in the surgery of ocular surface disorders.

Authors:  Ronald M Sanchez-Avila; Jesús Merayo-Lloves; Ana C Riestra; Silvia Berisa; Carlos Lisa; José Alfonso Sánchez; Francisco Muruzabal; Gorka Orive; Eduardo Anitua
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

8.  Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study.

Authors:  Jorge L Alio; Alejandra E Rodriguez; Renan Ferreira-Oliveira; Dominika Wróbel-Dudzińska; Ahmed A Abdelghany
Journal:  Ophthalmol Ther       Date:  2017-08-08

9.  Construction of a Corneal Stromal Equivalent with SMILE-Derived Lenticules and Fibrin Glue.

Authors:  Houfa Yin; Peijin Qiu; Fang Wu; Wei Zhang; Wenqi Teng; Zhenwei Qin; Chao Li; Jiaojie Zhou; Zhi Fang; Qiaomei Tang; Qiuli Fu; Jian Ma; Yabo Yang
Journal:  Sci Rep       Date:  2016-09-21       Impact factor: 4.379

10.  Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma.

Authors:  Ronald M Sánchez-Avila; Jesus Merayo-Lloves; Maria Laura Fernández; Luis Alberto Rodríguez-Gutiérrez; Pedro Pablo Rodríguez-Calvo; Andres Fernández-Vega Cueto; Francisco Muruzabal; Gorka Orive; Eduardo Anitua
Journal:  Int Med Case Rep J       Date:  2018-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.